# Climb Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/climb-bio

- Industry: Biotechnology
- Headquarters: Wellesley, US
- Website: www.climbbio.com/
- Total disclosed funding: $60M
- Latest round: Series B (May 21, 2021)
- Investors on record: 6

## About

Founded in 2018 and based in Washington, US, Climb Bio, Inc., formerly known as Eliem Therapeutics, Inc. is a biotechnology company that develops treatments for neuronal excitability disorders. Andrew Levin and Valerie Morisset co-founded the company. As of May 2021, the company has raised a total of 4 funding rounds. In August 2021, Eliem became a public company with a total offering of USD 12.50 per share, under the ticker symbol ELYM. In June 2024, Eliem Therapeutics, Inc. raised USD 120 million in venture funding from investors. The company's R&D team offers therapies for central and peripheral nervous system disorders that include a variety of common conditions such as chronic pain, depression, epilepsy, and anxiety to enhance a patients’ quality of life. Eliem Therapeutics's pipeline of preclinical candidates includes ETX-810 palmitoylethanolamide (PEA) prodrug for chronic pain and ETX-155 gamma-aminobutyric acid (GABAA) positive allosteric modulator (PAM) for major depressive disorder, hormone-related mood disorders, and focal onset seizures.

## Funding rounds

- Series B, May 21, 2021, $60M — Intermediate Capital Group, Access Industries, Samlyn Capital, RA Capital Management, Acorn Bioventures, LifeArc

## Investors

- Intermediate Capital Group — Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B
- Samlyn Capital — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series B
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Series B